Arginine/asymmetric dimethylarginine ratio and cardiovascular risk factors in patients with predialytic chronic kidney disease

Clinical Biochemistry

Volumn 44, Issue 8-9, 2011, Pages 642-646

  Hov, Gunhild Garmo ^a   Sagen, Erling ^a   Hatlen, Gudrun ^a   Bigonah, Arash ^a   Åsberg, Arne ^a   Aasarød, Knut ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Arginine; Asymmetric dimethylarginine; Cardiovascular risk; Chronic kidney disease; Nitric oxide

Indexed keywords

ACETYLSALICYLIC ACID; ALFACALCIDOL; ALLOPURINOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE ACID PROTEIN; INSULIN; LOOP DIURETIC AGENT; N(G),N(G) DIMETHYLARGININE; THIAZIDE DIURETIC AGENT; WARFARIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOKING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARGININE; CARDIOVASCULAR DISEASES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 79955843551     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.03.024     Document Type: Article

References (45)

1. Vallance P., Chan N. Endothelial function and nitric oxide: clinical relevance. Heart 2001, 85:342-350.
2. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43:109-142.
3. Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109:III27-III32.
4. Go A.S., Chertow G.M., Fan D.J., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
5. Schiffrin E.L., Lipman M.L., Mann J.F. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007, 116:85-97.
6. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Ren Physiol 2008, 294:F1-F9.
7. Moncada S., Higgs A. The l-arginine-nitric oxide pathway. N Engl J Med 1993, 329:2002-2012.
8. Closs E.I., Basha F.Z., Habermeier A., Forstermann U. Interference of l-arginine analogues with l-arginine transport mediated by the y+ carrier hcat-2b. Nitric Oxide 1997, 1:65-73.
9. Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339:572-575.
10. Zoccali C., Bode-Boger S., Mallamaci F., Benedetto F., Tripepi G., Malatino L., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358:2113-2117.
11. MacAllister R.J., Rambausek M.H., Vallance P., Williams D., Hoffmann K.H., Ritz E. Concentration of dimethyl-l-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 1996, 11:2449-2452.
12. Ravani P., Tripepi G., Malberti F., Testa S., Mallamaci F., Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005, 16:2449-2455.
13. Fliser D., Kronenberg F., Kielstein J.T., Morath C., Bode-Boger S.M., Haller H., et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005, 16:2456-2461.
14. Marescau B., Nagels G., Possemiers I., De Broe M.E., Becaus I., Billiouw J.M., et al. Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 1997, 46:1024-1031.
15. Al Banchaabouchi M., Marescau B., Possemiers I., D'Hooge R., Levillain O., De Deyn P.P. Ng, ng-dimethylarginine and ng, ng-dimethylarginine in renal insufficiency. Pflugers Arch 2000, 439:524-531.
16. Young J.M., Terrin N., Wang X., Greene T., Beck G.J., Kusek J.W., et al. Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol 2009, 4:1115-1120.
17. Shi B., Ni Z., Zhou W., Yu Z., Gu L., Mou S., et al. Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease. Eur J Intern Med 2010, 21:444-448.
18. Boger R.H. Asymmetric dimethylarginine (adma) and cardiovascular disease: insights from prospective clinical trials. Vasc Med 2005, 10(Suppl 1):S19-S25.
19. Fleck C., Janz A., Schweitzer F., Karge E., Schwertfeger M., Stein G. Serum concentrations of asymmetric (adma) and symmetric (sdma) dimethylarginine in renal failure patients. Kidney Int Suppl 2001, 78:S14-S18.
20. Kielstein J.T., Boger R.H., Bode-Boger S.M., Frolich J.C., Haller H., Ritz E., et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002, 13:170-176.
21. Tarnow L., Hovind P., Teerlink T., Stehouwer C.D., Parving H.H. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004, 27:765-769.
22. Brunini T.M., Moss M.B., Siqueira M.A., Santos S.F., Lugon J.R., Mendes-Ribeiro A.C. Nitric oxide, malnutrition and chronic renal failure. Cardiovasc Hematol Agents Med Chem 2007, 5:155-161.
23. Blum A., Hathaway L., Mincemoyer R., Schenke W.H., Kirby M., Csako G., et al. Oral l-arginine in patients with coronary artery disease on medical management. Circulation 2000, 101:2160-2164.
24. Bode-Boger S.M., Scalera F., Ignarro L.J. The l-arginine paradox: importance of the l-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther 2007, 114:295-306.
25. Yin W.H., Chen J.W., Tsai C., Chiang M.C., Young M.S., Lin S.J. l-arginine improves endothelial function and reduces ldl oxidation in patients with stable coronary artery disease. Clin Nutr 2005, 24:988-997.
26. Jacobi J., Tsao P.S. Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review. Am J Nephrol 2008, 28:224-237.
27. Celik T., Iyisoy A., Yuksel C., Jata B. The beneficial effects of angiotensin-converting enzyme inhibitors on serum asymmetric dimethylarginine levels in the patients with cardiovascular disease. Int J Cardiol 2010, 142:107-109.
28. Teerlink T., Nijveldt R.J., de Jong S., van Leeuwen P.A. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002, 303:131-137.
29. Hov G.G., Sagen E., Bigonah A., Asberg A. Health-associated reference values for arginine, asymmetric dimethylarginine (adma) and symmetric dimethylarginine (sdma) measured with high-performance liquid chromatography. Scand J Clin Lab Invest 2007, 67:868-876.
30. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999, 130:461-470.
31. Altman D.G. Practical statistics for medical research 1991, Chapman & Hall, London, p. 336-51. 1 ed.
32. Matsuguma K., Ueda S., Yamagishi S.I., Matsumoto Y., Kaneyuki U., Shibata R., et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 2006, 17:2176-2183.
33. Ueda S., Yamagishi S., Okuda S. New pathways to renal damage: role of adma in retarding renal disease progression. J Nephrol 2010, 23:377-386.
34. Sydow K., Fortmann S.P., Fair J.M., Varady A., Hlatky M.A., Go A.S., et al. Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin Chem 2010, 56:111-120.
35. Jeserich M., Munzel T., Just H., Drexler H. Reduced plasma l-arginine in hypercholesterolaemia. Lancet 1992, 339:561.
36. Mendes Ribeiro A.C., Roberts N.B., Lane C., Yaqoob M., Ellory J.C. Accumulation of the endogenous l-arginine analogue ng-monomethyl-l-arginine in human end-stage renal failure patients on regular haemodialysis. Exp Physiol 1996, 81:475-481.
37. Landray M.J., Emberson J.R., Blackwell L., Dasgupta T., Zakeri R., Morgan M.D., et al. Prediction of esrd and death among people with ckd: the chronic renal impairment in birmingham (crib) prospective cohort study. Am J Kidney Dis 2010, 56:1082-1094.
38. Beltowski J., Kedra A. Asymmetric dimethylarginine (adma) as a target for pharmacotherapy. Pharmacol Rep 2006, 58:159-178.
39. Kawata T., Daimon M., Hasegawa R., Teramoto K., Toyoda T., Sekine T., et al. Effect of angiotensin-converting enzyme inhibitor on serum asymmetric dimethylarginine and coronary circulation in patients with type 2 diabetes mellitus. Int J Cardiol 2009, 132:286-288.
40. Delles C., Schneider M.P., John S., Gekle M., Schmieder R.E. Angiotensin converting enzyme inhibition and angiotensin ii at1-receptor blockade reduce the levels of asymmetrical n(g), n(g)-dimethylarginine in human essential hypertension. Am J Hypertens 2002, 15:590-593.
41. Wang J., Sim A.S., Wang X.L., Salonikas C., Naidoo D., Wilcken D.E. Relations between plasma asymmetric dimethylarginine (adma) and risk factors for coronary disease. Atherosclerosis 2006, 184:383-388.
42. Schiel R., Franke S., Busch M., Muller A., Fleck C., Muller U.A., et al. Effect of smoking on risk factors for cardiovascular disease in patients with diabetes mellitus and renal insufficiency. Eur J Med Res 2003, 8:283-291.
43. Maas R., Schulze F., Baumert J., Lowel H., Hamraz K., Schwedhelm E., et al. Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based monitoring of trends and determinants in cardiovascular disease/kooperative gesundheitsforschung in der region augsburg study and experimental data. Clin Chem 2007, 53:693-701.
44. Boger R.H., Maas R., Schulze F., Schwedhelm E. Asymmetric dimethylarginine (adma) as a prospective marker of cardiovascular disease and mortality-an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 2009, 60:481-487.
45. O'Kane P., Xie L., Liu Z., Queen L., Jackson G., Ji Y., et al. Aspirin acetylates nitric oxide synthase type 3 in platelets thereby increasing its activity. Cardiovasc Res 2009, 83:123-130.